Tris Pharma, Inc.’s recent voluntarily recall of infants’ ibuprofen sold at retailers Walmart, CVS Pharmacy and Family Dollar, has expanded to include 3 additional lots of the product.
In December, the pharma maker voluntarily recalled 3 lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP, 50 mg per 1.25 ml, because they potentially have higher concentrations of ibuprofen.
Related: Pharma makers recall 2 important drugs
Certain lots of CVS, Walmart, and Family Dollar private label infants’ ibuprofen were included in the December recall, while the new recall includes different lots of CVS private label infants’ ibuprofen as well as lots of Walmart’s Equate private label ibuprofen and Family Dollar’s Family Wellness private label product.
“There is a remote possibility that infants, who may be more susceptible to a higher potency level of drug…may be more vulnerable to permanent NSAID-associated renal injury,” the New Jersey pharma maker said in a statement.
The newly recalled lots include Walmart’s Equate brand of infants’ ibuprofen with expiration dates of 2/19, 4/19, and 8/19; CVS Health’s brand of infants’ ibuprofen with an expiration date of 8/19; and Family Dollar’s Family Wellness brand with an expiration date of 8/19.
Related: Blood pressure drug recall expands
Adverse effects could include nausea, vomiting, epigastric pain, or more rarely, diarrhea. Tinnitus, headache and gastrointestinal bleeding are also possible adverse effects. However, Tris Pharma has not received any reports of adverse events related to the recalled lots.
Consumers with questions about the recall can contact Tris Customer Service at 732-940-0358 or via email.
Read more: FDA warns maker of ingredient in huge heart drug recall
FDA and EMA Accepts Applications for New Nusinersen Regimen
January 23rd 2025An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
Read More
Trump Impact on Medicare Drug Price Negotiations Uncertain
Published: January 22nd 2025 | Updated: January 22nd 2025Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.
Read More